 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies Company NYSE: SQZ, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical regenerative medicine data showing that the companys Cell Squeeze technology can be used to generate neurons from induced human pluripotent stem cells iPSCs through the single delivery of an mRNA encoding fate-specifying transcription factor. The new findings build upon recent clinical and pre-clinic 